SynthesisDermatologic therapy2021
COVID-19 and exacerbation of dermatological diseases: A review of the available literature.
Synthesis in Dermatologic therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- COVID-19 and exacerbation of dermatological diseases: A review of the available literature.Dermatologic therapy · 2021Pooled it
- The Global Burden and Temporal Trends of Psoriasis, 1990-2021: Implications From the COVID-19 Pandemic.Health science reports · 2026Article
- Advances in Psoriasis Research: Decoding Immune Circuits and Developing Novel Therapies.International journal of molecular sciences · 2025Review
- Risk Factors for Flares and New Lesions of Hidradenitis Suppurativa Following COVID-19 Disease: A Retrospective Cohort Study of 310 Patients in Greece.Microorganisms · 2025Article
- Current treatment of Psoriasis triggered by Cytokine Storm and future immunomodulation strategies.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Prevalence, outcomes and associated factors of SARS-CoV-2 infection in psoriasis patients of Southwest China: a cross-sectional survey.Scientific reports · 2024Article
- Cutaneous Reactions after COVID-19 Vaccines: Analysis of the Clinical and Histopathological Spectrum-Case Series and Review of the Literature.Dermatopathology (Basel, Switzerland) · 2024Article
- A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks.Dermatology reports · 2024Article
- Article
- Restoring immune tolerance in pemphigus vulgaris.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Risk Factors for Psoriasis Flares: A Narrative Review.Psoriasis (Auckland, N.Z.) · 2024Review
- Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries.Psoriasis (Auckland, N.Z.) · 2024Article
- Exacerbation of Behcet's Disease and Pyoderma Gangrenosum Following COVID-19 Infection: A Case Report.Cureus · 2023Article
- An Erythrodermic Psoriasis Flare-Up With Staphylococcus Bacteremia Secondary to COVID-19 Infection: A Case Report.Cureus · 2023Article
- Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19.Tropical medicine and infectious disease · 2023Article
- Biologics targeting IL-17 and IL-23 maintain stability in patients with psoriasis during COVID-19 infection: a case-control study.Frontiers in medicine · 2023Article
- Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case-Control Study.Biomedicines · 2022Article
- Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study.Vaccines · 2022Article
- Characteristics of hair loss after COVID-19: A systematic scoping review.Journal of cosmetic dermatology · 2022Article
- Spontaneous complete resolution of alopecia totalis post SARS-CoV-2 infection.JAAD case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the emergence of the new coronavirus disease 19 (COVID-19) pandemic, there has been a concern for the patients with chronic autoimmune diseases including dermatological conditions over the potential exacerbation of these underlying conditions after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). We performed a systematic review to evaluate presentations, postinfection change in the manifestation, diagnosis, and management of flare-ups of underlying dermatologic disease in patients with COVID-19. A total of 17 articles were recovered reporting on flare-ups of dermatological disease including pemphigus vulgaris, psoriasis, subacute cutaneous lupus erythematosus, acrodermatitis continua of Hallopeau, systemic sclerosis sine scleroderma, and Sézary syndrome (SS). Out of these, psoriasis and alopecia areata were the most common conditions. However, most cases of psoriasis could have been attributed to either antimalarial agents that were initially used for the treatment of COVID-19 or discontinuation of treatment following SARS-CoV2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.